Synlogic, Inc.

Synlogic, Inc. is a clinical-stage biopharmaceutical company focused on developing synthetic biotic medicines for metabolic and immunological diseases. The company's product pipeline includes orally administered, non-systemically absorbed drug candidates such as SYNB1618 and SYNB1934, currently in Phase II clinical trials for phenylketonuria treatment, and SYNB1353 for homocystinuria. Additionally, SYNB8802 is in Phase I clinical trial for enteric hyperoxaluria. Synlogic is also developing SYNB1891, an intratumorally administered synthetic biotic medicine for solid tumors and lymphoma. The company generates revenue through collaborations with F. Hoffmann-La Roche Ltd, Hoffmann-La Roche Inc., and Ginkgo Bioworks, Inc.

Products

• SYNB1618

• SYNB1934

• SYNB1353

• SYNB8802

• SYNB1891